Verition Fund Management LLC Invests $477,000 in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Verition Fund Management LLC purchased a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,353 shares of the company's stock, valued at approximately $477,000. Verition Fund Management LLC owned about 0.17% of Jasper Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Ally Bridge Group NY LLC increased its holdings in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after buying an additional 180,852 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics during the second quarter valued at $740,000. American Century Companies Inc. grew its holdings in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock valued at $322,000 after purchasing an additional 3,032 shares during the period. MetLife Investment Management LLC raised its stake in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after buying an additional 3,873 shares during the period. Finally, Wolff Wiese Magana LLC purchased a new position in shares of Jasper Therapeutics during the 3rd quarter valued at about $59,000. Institutional investors own 79.85% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating for the company in a report on Wednesday, August 14th. Evercore ISI reaffirmed an "outperform" rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. HC Wainwright reissued a "buy" rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. JMP Securities reaffirmed a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Finally, BMO Capital Markets initiated coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $63.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $73.38.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR traded down $2.00 during trading on Thursday, hitting $20.47. The company had a trading volume of 155,882 shares, compared to its average volume of 175,119. The stock has a market cap of $307.07 million, a price-to-earnings ratio of -4.32 and a beta of 2.18. The company has a fifty day simple moving average of $20.91 and a two-hundred day simple moving average of $20.89. Jasper Therapeutics, Inc. has a one year low of $4.00 and a one year high of $31.01.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.